1. MAPK/ERK Pathway
    Autophagy
    Apoptosis
  2. p38 MAPK
    Autophagy
    Apoptosis
  3. SB 202190

SB 202190 

Cat. No.: HY-10295 Purity: 99.89%
Handling Instructions

SB 202190 est un inhibiteur séléctive de p38 MAP kinase avec des IC50s de 50 nM et 100 nM pour p38α et p38β2, respectivement. SB 202190 se lie à la poche ATP de la kinase p38 humaine recombinante active avec un Kd de 38 nM. SB 202190 a une activité anticancéreuse et a sauvé les déficits de mémoire.

SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy.

For research use only. We do not sell to patients.

SB 202190 Chemical Structure

SB 202190 Chemical Structure

CAS No. : 152121-30-7

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 66 In-stock
Estimated Time of Arrival: December 31
Solid
50 mg USD 60 In-stock
Estimated Time of Arrival: December 31
100 mg USD 106 In-stock
Estimated Time of Arrival: December 31
200 mg USD 198 In-stock
Estimated Time of Arrival: December 31
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 54 publication(s) in Google Scholar

Other Forms of SB 202190:

Top Publications Citing Use of Products

46 Publications Citing Use of MCE SB 202190

    SB 202190 purchased from MCE. Usage Cited in: EBioMedicine. 2015 Nov 19;2(12):1944-56.

    SW620 xenograft tumors are treated with SB202190 and OSI027 individually or in combination. The effect on signaling by p38 (P-MK2 and P-Hsp27) and mTOR (P-S6K1 and P-AKT) is analyzed by immunoblot. SB202190 achieves on-target inhibition by diminishes phosphorylation of MK2 and Hsp27. OSI-027 blocks signaling by both mTORC1 and mTORC2 by decreases phosphorylation of S6K1 and AKT. When SB202190 and OSI-027 are used in combination, all three kinases, p38, mTORC1 and mTORC2 are potently inhibited.

    SB 202190 purchased from MCE. Usage Cited in: Int J Mol Med. 2017 Jan;39(1):71-80.

    Inhibition of p38 expression enhances the promoting effect of miR-214 on the adipocyte differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) following the overexpression of miR-214. p-p38 protein expression decreases following treatment with p38 inhibitor, as shown by (A) western blot analysis, and (B) statistical analysis of p-p38 protein expression.

    SB 202190 purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2017;2017:7426458.

    Representative immunoblot analysis of p53, p16, p21, and retinoblastoma protein (Rb) in NP cells.

    SB 202190 purchased from MCE. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    The Western blot analysis of HOG1 and Phospho-HOG1.

    SB 202190 purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    SB 202190 purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Oct 19;15(1):291.

    Blocking the three MAPK signaling pathways through specific inhibitors (U0126; SB202190; and SP600125) significantly decrease the infection-induced neuroinflammatory response via real-time PCR analysis.

    SB 202190 purchased from MCE. Usage Cited in: J Cell Biochem. 2019 Mar;120(3):3898-3910.

    Cells pretreated with SP600125 show a decreased proapoptotic Bax expression and increase antiapoptotic Bcl-2 formation when JNK pathway is blocked. Inhibition of p38 by SB202190 significantly enhanced Bcl-2 expression. Pretreatment with BAY 11-7082 to inhibit NF‐κB markedly enhance Baxm and decrease Bcl-2 expression compared with the ACR-treated group.

    SB 202190 purchased from MCE. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374.

    MAPKs inhibitors suppress LPS-induced COX-2 expression and AKT1 phosphorylation. RAW264.7 cells are pretreated for 1 h with U0126, SB202190, SP600125 alone, or all the three inhibitors, respectively, and then exposed to 40 ng/ml LPS for 30 min or 12 h. The phosphorylated protein kinases and COX-2 expression are detected by western blot analysis using their corresponding antibodies.

    View All p38 MAPK Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits[1][2]. SB202190 induces autophagy[3].

    IC50 & Target[1]

    p38α

    50 nM (IC50)

    p38β2

    100 nM (IC50)

    In Vitro

    SB 202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner[1].
    SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480)[2].
    In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 4-week-old female BALB/c nude mice (bearing SW480 and RKO xenograft tumors)[2]
    Dosage: 5 mg/kg
    Administration: Intraperitoneal injection; daily for 10-12 days
    Result: Inhibition of tumor cell survival and tumor growth.
    Molecular Weight

    331.34

    Formula

    C20H14FN3O

    CAS No.
    SMILES

    FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2)C=C1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (301.80 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.0180 mL 15.0902 mL 30.1805 mL
    5 mM 0.6036 mL 3.0180 mL 6.0361 mL
    10 mM 0.3018 mL 1.5090 mL 3.0180 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

    *All of the co-solvents are available by MCE.
    References

    Purity: 99.89%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    SB 202190
    Cat. No.:
    HY-10295
    Quantity:
    MCE Japan Authorized Agent: